drugset / Trial / NCT01467401
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.
Timeline
- Start
- 2002-08-19
- Primary completion
- 2003-05-15
- Completion
- 2003-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | biphasic human insulin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | biphasic insulin aspart | Protein / enzyme biologic | — | Subcutaneous |